Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-35.16 Insider Own67.76% Shs Outstand11.94M Perf Week-9.88%
Market Cap222.20M Forward P/E- EPS next Y-4.59 Insider Trans-0.28% Shs Float3.85M Perf Month-36.70%
Income-112.96M PEG- EPS next Q-1.00 Inst Own8.46% Short Float1.56% Perf Quarter12.91%
Sales1.16M P/S191.55 EPS this Y47.05% Inst Trans-18.57% Short Ratio1.43 Perf Half Y85.58%
Book/sh22.65 P/B0.82 EPS next Y-16.99% ROA-42.26% Short Interest0.06M Perf Year0.38%
Cash/sh6.92 P/C2.69 EPS next 5Y-9.40% ROE-90.02% 52W Range8.24 - 32.88 Perf YTD70.05%
Dividend Est.- P/FCF- EPS past 5Y-0.07% ROI-154.76% 52W High-43.40% Beta-0.33
Dividend TTM- Quick Ratio7.25 Sales past 5Y199.24% Gross Margin-11.33% 52W Low125.74% ATR (14)1.94
Dividend Ex-Date- Current Ratio7.25 EPS Y/Y TTM-2264.74% Oper. Margin-7967.30% RSI (14)30.11 Volatility5.24% 8.27%
Employees7 Debt/Eq0.02 Sales Y/Y TTM-63.97% Profit Margin-9771.71% Recom1.00 Target Price49.67
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q53.43% Payout- Rel Volume0.60 Prev Close19.68
Sales Surprise- EPS Surprise-347.35% Sales Q/Q-100.00% EarningsMay 09 BMO Avg Volume41.92K Price18.61
SMA20-27.45% SMA50-27.28% SMA2003.68% Trades Volume25,068 Change-5.44%
Date Action Analyst Rating Change Price Target Change
May-21-24Initiated Leerink Partners Outperform $54
Apr-11-24Initiated Oppenheimer Outperform $50
Apr-02-24Initiated Piper Sandler Overweight $45
Jul-28-23Downgrade Robert W. Baird Outperform → Neutral $9 → $1.50
Feb-22-22Reiterated BTIG Research Neutral $35 → $29
Feb-22-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-22-22Downgrade Oppenheimer Outperform → Perform
Mar-02-21Initiated Stifel Hold $14
Dec-14-20Resumed H.C. Wainwright Buy $30
Aug-11-20Reiterated H.C. Wainwright Buy $37 → $30
May-09-24 01:56PM
Apr-03-24 07:00AM
Mar-18-24 04:30PM
Mar-15-24 09:52PM
10:48AM Loading…
Mar-01-24 10:48AM
Jan-27-24 12:10PM
Jan-03-24 04:08PM
Nov-17-23 06:40AM
Nov-16-23 12:18PM
Nov-14-23 05:02PM
Aug-14-23 04:20PM
04:05PM Loading…
Jul-27-23 04:05PM
Jul-06-23 11:17AM
May-16-23 08:00AM
May-11-23 05:35PM
May-03-23 07:30AM
Mar-27-23 05:52AM
Mar-15-23 04:01PM
Mar-09-23 06:45PM
Mar-02-23 07:30AM
Feb-24-23 05:31AM
04:01PM Loading…
Feb-22-23 04:01PM
Jan-05-23 09:25AM
Jan-04-23 04:01PM
Nov-12-22 08:08AM
Nov-10-22 05:45PM
Oct-27-22 09:00AM
Oct-06-22 08:30AM
Sep-27-22 08:15AM
Sep-08-22 11:05AM
Sep-06-22 04:01PM
Aug-17-22 01:05PM
Aug-16-22 11:52AM
Aug-15-22 06:15PM
Aug-12-22 07:46AM
Aug-11-22 04:05PM
Jul-25-22 09:12AM
Jul-05-22 08:30AM
Jun-29-22 08:00AM
Jun-13-22 08:00AM
Jun-10-22 08:30AM
May-18-22 06:00AM
May-16-22 06:05PM
May-13-22 08:45AM
May-02-22 04:56PM
Apr-21-22 08:30AM
Mar-23-22 05:45PM
Mar-10-22 04:01PM
Mar-08-22 10:00AM
Mar-07-22 09:38AM
Mar-03-22 03:00PM
Feb-24-22 08:45AM
Feb-23-22 10:00AM
Feb-22-22 07:34AM
Feb-21-22 09:40AM
Feb-18-22 04:05PM
Feb-10-22 11:40AM
Feb-02-22 09:40AM
Jan-28-22 10:46AM
Jan-21-22 09:38AM
Dec-12-21 08:19AM
Dec-10-21 06:38PM
Nov-15-21 07:10AM
Nov-03-21 08:29AM
Nov-01-21 03:01PM
Oct-21-21 07:00AM
Oct-20-21 08:30AM
Oct-18-21 08:30AM
Oct-13-21 08:21AM
Oct-12-21 04:05PM
Oct-11-21 08:39AM
Aug-14-21 03:27AM
Aug-12-21 07:05PM
Aug-05-21 08:30AM
Aug-04-21 08:30AM
Aug-02-21 03:01PM
Jun-19-21 05:23AM
May-13-21 07:00AM
May-06-21 06:15PM
May-03-21 08:00AM
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alloway PaulSee RemarksMar 25 '24Sale24.212686,4882,596Apr 23 05:03 PM
Michaud Charles JrSee RemarksMar 25 '24Sale24.20751,815927Apr 23 05:00 PM
TZIANABOS ARTHURDirectorJan 09 '24Sale0.5713,0377,445128,778Feb 15 04:33 PM
Alloway PaulSee RemarksJan 03 '24Sale0.577,2804,12028,036Jan 05 05:54 PM
Michaud Charles JrSee RemarksJan 03 '24Sale0.571,70897511,598Jan 05 05:49 PM
Seymour AlbertSee RemarksSep 06 '23Sale1.151,4481,665150,874Sep 08 04:44 PM
Jordan JulieChief Medical OfficerAug 03 '23Option Exercise0.006,57908,804Aug 07 09:39 PM
Jordan JulieChief Medical OfficerAug 03 '23Sale1.391,8532,5763,882Aug 07 09:39 PM
Jordan JulieChief Medical OfficerAug 02 '23Option Exercise0.0035002,869Aug 04 04:08 PM
Jordan JulieChief Medical OfficerAug 02 '23Sale1.31991302,770Aug 04 04:08 PM